Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases

Смакотина, С. А.; Zelendinova, A R; Bondareva, Irina; Бернс, С. А.

doi:10.17116/terarkh201587972-76

Cited by 4 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides its cholesterol-lowering properties, atorvastatin also possesses pleiotropic anti-inflammatory effects that could help the management of RA activity. [7][8][9][10][11][12][13][14][15][17][18][19][20]22 The pooled results of the present systematic review and meta-analysis of 8 RCTs support that atorvastatin could be added to DMARDs in patients with RA for disease control, but it has to be noted that the heterogeneity of the available data was high.…”

Section: Discussionmentioning

confidence: 74%

“…Finally, 36 full-text articles or abstracts were assessed for eligibility, of which 26 were deemed ineligible for a number of reasons. A total of 10 RCTs 9,10,12,14,15,17,19,20,22,37 were included in the qualitative synthesis.…”

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

“…In recent years, numerous studies have demonstrated that statins can contribute to the anti-inflammatory management of RA symptoms 7–22 . Statins are a class of lipid-lowering agents and prevent the production of cholesterol in the liver by inhibiting the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase 23,24 .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Atorvastatin Plus Conventional Disease-Modifying Antirheumatic Drugs on Disease Activity in Rheumatoid Arthritis

Hou¹,

Guo

Chen

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of atorvastatin plus disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). Methods:We queried the PubMed, Embase, Web of Science, and the CENTRAL (Cochrane Central Register of Controlled Trials) databases for this study. The pooled efficacy was evaluated using standardized mean differences. The inverse of the variance model was used for data pooling.Results: Based on the search, we identified 9 randomized controlled trials. The trials included 258 patients in the atorvastatin plus DMARD groups and 246 patients in the DMARD alone groups. The primary outcome was the change from baseline in the 2018 (209:228 Disease Activity Score in 28 Joints). Based on the Disease Activity Score in 28 Joints, disease activity in RA patients decreased significantly in patients given atorvastatin plus DMARD compared with patients given DMARD alone (standardized mean difference, −2.46; 95% confidence interval, −3.98 to −0.95; p = 0.0015; I 2 = 97%; p < 0.01). Subgroup analysis did not identify any confounding factors, and no publication bias was detected in the meta-analysis. Conclusions:The result supports that atorvastatin could be added to DMARDs to treat patients with RA.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Search Results and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Atorvastatin Plus Conventional Disease-Modifying Antirheumatic Drugs on Disease Activity in Rheumatoid Arthritis

Hou¹,

Guo

Chen

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…After screening, 19 studies were finally included, and the basic information is shown in Table 1. In these included articles published between 2004 and 2020, a total of 22,906 patients were enrolled, with 14 studies using atorvastatin at doses ranging from 10 to 80 mg qd, [22][23][24][25][26][27][28][29][30][31][32][33][34][35] 2 studies using simvastatin at doses ranging from 5 to 10 mg qd, [36,37] and 3 studies using rosuvastatin at a dose of 20 mg qd. [38][39][40] The duration of therapy ranged from 8 weeks to 12 years and most of the subjects were women.…”

Section: Basic Characteristics and Study Qualitymentioning

confidence: 99%

The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis

Ren,

2023

Medicine

View full text Add to dashboard Cite

Background: A large body of research has investigated the use of statins in rheumatoid arthritis (RA); however, the therapeutic effects of statins remain uncertain. Thus, we designed a systematic review and meta-analysis to evaluate the role of statins in patients with RA. Methods: Databases searched to detect clinical randomized controlled trials or clinical controlled trials on the interaction between statins and RA before January 2020 included PubMed, Web of Sciences, Embase, Cochrane Library, CNKI, Wan Fang Database. Efficacy was measured by Disease Activity Score in 28 Joints (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tenderness of the joint (TJ), swelling of the joint (SJ), and interleukin-6. The level of blood lipid was also evaluated. STATA 12.0 was used for the meta-analysis. The Cochrane method was used for quality assessment. Heterogeneity was considered to determine fixed effects or random effects models. Results: Nineteen clinical trials with a total of 22,906 subjects were included in the meta-analysis. Sixteen studies reported a change in DAS28 after statin treatment. The pooled analysis showed that statins reduced DAS28 in RA patients. Change in ESR after statin treatment was reported in 9 studies. The summary analysis showed that statins lowered ESR in RA patients. Twelve studies reported a change in CRP after statin treatment. The results of the entire analysis showed that statins lowered CRP in RA patients. Seven studies reported a change in TJ after statin treatment. The combined analysis showed that statins reduced TJ at RA patients. Six studies reported changes in IL6 after statin therapy. The results showed that statins failed to reduce IL6 in RA patients. Seven studies reported changes in SJ after statin therapy, which showed that statins failed to reduce SJ in RA patients. We also found that statins can reduce blood lipid levels in RA patients. Conclusion: In conclusion, statins were able to reduce DAS28, ESR, CRP, TJ, and blood lipids. It indicated that stains can benefit patients with RA by inhibiting the expression of inflammatory factors and reducing the levels of lipids in the blood. Our study may offer a new perspective on the treatment of RA and provide research ideas for future larger multi-center clinical trials.

show abstract

“…Some kinds of statins that are commonly used for the treatment of hypercholesterolemia can block lymphocyte function-associated antigen1mediated cell adhesion and co-stimulation doi:10.15171/ipp.2019.09 of T lymphocytes (17). This evidence suggests the effects of statin suppressant effects on the immune system (18,19). In some experimental autoimmune encephalomyelitis, a CD4 T cell-mediated disease model of multiple sclerosis, atorvastatin prevents or reverses chronic and relapsing paralysis (20,21).…”

Section: Key Pointmentioning

confidence: 99%

Anti-inflammatory effects of different statins in rheumatoid arthritis; a randomized double-blind controlled clinical trial

Karimifar¹,

Salesi²,

Ghasemian³

et al. 2019

Immunopathol Persa

View full text Add to dashboard Cite

Introduction: Statin family drugs are lipid-lowering agents with anti-inflammatory effects. Objectives: The aim of our study was to evaluate anti-inflammatory effects of different statins in rheumatoid arthritis patients. Patients and Methods: Around 161 eligible subjects with rheumatoid arthritis were enrolled. They randomly were divided into three groups. The first group received 40 mg/daily atorvastatin, the second group received 40 mg/daily simvastatin, and the third group received placebo as control for six months. To calculate the disease activity, DAS-28 (Disease Activity Score 28) was used while VAS (visual analog scale) was used to assess the severity of pain in rheumatoid arthritis patients. DAS-28, erythrocyte sedimentation rates (ESR) and lipid profiles were assessed once for the baseline and then after three and six months of intervention. Data was analyzed by SPSS by a P value <0.05 which was set to be significant.

show abstract

Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases

Cited by 4 publications

References 22 publications

Efficacy of Atorvastatin Plus Conventional Disease-Modifying Antirheumatic Drugs on Disease Activity in Rheumatoid Arthritis

Efficacy of Atorvastatin Plus Conventional Disease-Modifying Antirheumatic Drugs on Disease Activity in Rheumatoid Arthritis

The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis

Anti-inflammatory effects of different statins in rheumatoid arthritis; a randomized double-blind controlled clinical trial

Contact Info

Product

Resources

About